Psychopharmacology

TAAR1 Agonism: A Novel Approach to Schizophrenia Management

Saturday, June 4, 2022

1:40 PM – 2:40 PM PT

Location: Octavius 11

This activity has been supported through an independent educational grant from Sunovion Pharmaceuticals Inc.

Despite profound burdens on the individual, family, and society, schizophrenia remains under-recognized and undertreated with more than half of the persons receiving suboptimal treatment or no mental health interventions at all. However, the mechanism of action (MOA) associated with TAAR1 agonism has the potential to transform management of schizophrenia. In this session, expert faculty will discuss the ongoing challenges in the management of schizophrenia, including the undertreatment and treatment nonadherence and how emerging therapies with diverse MOAs may fit into the evolving treatment paradigm.

Presenter(s)

Leslie L. Citrome, MD, MPH

Clinical Professor of Psychiatry and Behavioral Sciences
New York Medical College
Suffern, New York
Rebecca Kraus, MSPAS, PA-C

Physician Assistant
Southlake Psychiatry
Charlotte, North Carolina

Patient Presenter(s)

Bethany Yeiser, BS

President
CURESZ Foundation
Fairfield, Ohio